A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients1,2
Baboolal, KeshwarVolume:
75
Language:
english
Journal:
Transplantation
DOI:
10.1097/01.tp.0000063703.32564.3b
Date:
April, 2003
File:
PDF, 194 KB
english, 2003